Corvus Pharmaceuticals Reports Promising Interim Phase 1 Data for Soquelitinib in Atopic Dermatitis

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, updated the progress of its ongoing, randomized, double-blind, placebo-controlled phase 1 trial of soquelitinib in patients with moderate-to-severe atopic dermatitis The trial enrolled patients between the ages of 18 and 80 years with moderate-to-severe atopic dermatitis. The outcomes, in addition to having 10 more patients with a response at 28 days following the initiation of cohort 2, were considered safe and effective and revealed considerable improvement in objective clinically categorized parameters.

“Soquelitinib remains to show positive clinical benefit in atopic dermatitis,” said Richard A. Miller, M.D., the co-founder and chief executive officer of Corvus. Cohort 2, which examined the 200 mg daily dosing, actually displays improved effectivity compared to cohort 1 in terms of current regulatory parameters of IGA 0 or 1 and EASI 75. These endpoints demonstrate it as a new therapeutic resort since placebo patients could not achieve these standards within four weeks of treatment.

Referring back to Dr. Miller, soquelitinib offered many benefits, such as oral availability, safety, and different approaches acting as a selective inhibitor targeting parallel immune signaling pathways. This places the drug in good stead for the treatment of numerous immune diseases since the condition is well understood.

Next year, Corvus plans to finish enrollment for this trial and report detailed results in Q2 2025; other trials and programs Include the registration Phase 3 trial of the relapsed peripheral T cell lymphoma. Further advancement in soquelitinib provides the opportunity to address many unfulfilled needs in atopic dermatitis and other immunological diseases.